Frank Harder

Health Technology

Consumer Services

Commercial Services

Profile

Frank Harder formerly worked at Bioporto A, as Chief Financial Officer & IR Contact from 2007 to 2014, Zymenex A, as Chief Financial Officer, and PhaseOneTrials A, as Chief Financial Officer.
Mr. Harder received his graduate degree from the University of Copenhagen.

Former positions of Frank Harder

Companies	Position	End
BIOPORTO A/S	Director of Finance/CFO	31/12/2013
Zymenex A/S Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark.	Director of Finance/CFO	-
PhaseOneTrials A/S PhaseOneTrials A/S Miscellaneous Commercial ServicesCommercial Services PhaseOneTrials A/S is a Danish Contract Research Organization (CRO) that conducts clinical phase I trials and early phase II trials of new drug candidates. Phase I trials include studies in which a new drug is tested for the first time in healthy humans – also known as “First-in-Man” studies. Early phase II studies, or “Proof-of-Concept” studies, include testing a drug in small groups of patients to determine whether the drug has the desired effects on a given disease.	Director of Finance/CFO	-

See the detail of Frank Harder's experience

Training of Frank Harder

University of Copenhagen

Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Frank Harder's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
BIOPORTO A/S	Health Technology

Private companies	2
Zymenex A/S Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark.	Health Technology
PhaseOneTrials A/S PhaseOneTrials A/S Miscellaneous Commercial ServicesCommercial Services PhaseOneTrials A/S is a Danish Contract Research Organization (CRO) that conducts clinical phase I trials and early phase II trials of new drug candidates. Phase I trials include studies in which a new drug is tested for the first time in healthy humans – also known as “First-in-Man” studies. Early phase II studies, or “Proof-of-Concept” studies, include testing a drug in small groups of patients to determine whether the drug has the desired effects on a given disease.	Commercial Services